Natera Shares Surge on Stellar Quarterly Performance

Genetic testing specialist Natera has delivered a quarterly report that significantly surpassed market forecasts, propelling its stock upward. The company reported substantial revenue growth and margin expansion, concurrently raising its full-year guidance. However, this impressive performance is tempered by persistent financial losses, presenting a critical challenge for the high-flying equity.

Natera’s third quarter for fiscal year 2025 proved exceptionally strong. Company revenue surged 34.7% to reach $592.2 million, a jump primarily fueled by escalating demand for its diagnostic tests. The oncology segment demonstrated particularly vigorous expansion, with testing volumes climbing 53.9%.

The company’s profitability metrics also showed marked improvement. The gross margin advanced to 64.9%, indicating that Natera’s growth is becoming Read more...